Roche previously supported BaseLaunch from 2017 to 2019 during the company's first phase. Now in BaseLaunch's second phase of development, Roche is the first partner to be announced. More partners will be named in the coming months.
This second phase for BaseLaunch will do the following:
- Increase the funding per venture to a maximum of $500,000 U.S. versus $250,000 U.S. previously
- Establish the company as an "evergreen" permanent initiative
- Accept applications year-round rather than once a year
During BaseLaunch's first phase, it supported nine early therapeutic ventures that raised a total of more than $100 million U.S. in equity capital from U.S. and European venture funds. Recently, the company added another four ventures to its portfolio.
Applications are open until June 22, 2020.
Copyright © 2020 scienceboard.net